DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum

Information source: U.S. Army Medical Research and Materiel Command
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Malaria

Intervention: Placebo (Drug); Tafenoquine 25mg (Drug); Tafenoquine 50mg (Drug); Tafenoquine 100 mg (Drug); Tafenoquine 200 mg (Drug); Mefloquine 250 mg (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: U.S. Army Medical Research and Materiel Command

Official(s) and/or principal investigator(s):
Braden Hale, MD, Principal Investigator, Affiliation: US Naval Medical Research Unit


This was a randomised, double-blind, placebo-controlled study to compare the efficacy of a range four weekly doses of tafenoquine, and weekly mefloquine, with placebo as chemosuppression of P. falciparum malaria. Medications and placebo were matched and a double-dummy technique enabled blinding of tafenoquine versus mefloquine.

Clinical Details

Official title: A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum in Semi-immune Adults Living in the Kassena-Nankana District of Northern Ghana

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: First occurrence of malaria infection

Secondary outcome: Time to confirmation of parasitaemia


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Willing subjects in good general health.

- Males aged 18 to 60; females aged 50 to 60.

- Subjects who planned to stay in the study area until the end of the study.

Exclusion Criteria:

- Subjects with any cardiovascular, liver, neurologic, or renal function abnormality

which, in the opinion of the clinical investigators, would have placed them at increased risk of an adverse event or confused the result.

- Subjects with a personal or family history of seizures or frank psychiatric


- Females who had not ceased menstruation; a urine β-human chorionic gonadotrophin

(β-HCG) test was to be performed at screening females who had ceased menstruation to exclude pregnancy as a cause.

- Females who were lactating.

- Subjects given antimalarial drugs for treatment within two weeks of study drug


- Subjects with clinically significant abnormalities (to include but not limited

to abnormal hepatic or renal function) as determined by history, physical and routine blood chemistry and haematology values.

- Subjects with known hypersensitivity to any of the study drugs.

- Subjects unwilling to remain in the area, report for drug administration or

blood drawing during the 3-4 month duration of the study.

- Subjects with G6PD deficiency (as determined by two separate qualitative tests

per subject administered using distinct methods; methods used were visual dye and filter paper methods).

- Subjects with any of the following laboratory values: haemoglobin (Hb) <8g/dL,

platelets <80,000/mm3, white blood cell count (WBC) <3000/mm3, creatinine >1. 5mg/dL, alanine transaminase (ALT) >60IU or 1+ haematuria as detected by urine dipstick.

Locations and Contacts

Additional Information

Starting date: August 1998
Last updated: June 30, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017